...
首页> 外文期刊>Leukemia and lymphoma >T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors.
【24h】

T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors.

机译:成人T细胞非霍奇金淋巴瘤:临床病理特征,对治疗的反应和预后因素。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

T-cell NHL represent 10-15% of all malignant lymphomas making systematic prospective clinical trials difficult. Therefore, the prognostic significance of the T-cell phenotype has been a matter of controversy in recent years. In a retrospective analysis of 681 patients (pts) with NHL accrued from 1992 to 1997 at a single institution, 66 patients with T-cell NHL were identified. According to the REAL classification, histologies were as follows: 28 peripheral T-cell lymphomas (PTCL), 19 large cell anaplastic lymphoma (LCAL), 12 precursor lymphoblastic lymphoma (Lb), and seven AILD. Multiagent anthracycline containing regimens were used as initial therapy in 91% of cases. T-cell NHL represent 9.8% of all NHL patients at our institution accrued over a 6-year period. Overall response rate was 76%, 21% had progressive disease and 3% died during first line treatment. Mean overall survival (OS) was 8.22 +/- 0.94 years. There was a significant difference in OS between the four different histological subgroups (log rank P=0.0288). LCAL: mean OS 11.05 +/- 1.55 years (95% CI 8.00-14.09); LB: mean OS 7.09 +/- 1.40 years (95% CI 4.33-9.84); PTCL: mean 6.62 +/- 1.17 years (95% CI 4.33-8.90); AILD: 1.54 +/- 0.44 years (95% CI 0.67-2.40). OS was also significantly different for patients classified according to the International Prognostic Index (IPI)-score (log rank P = 0.002). Mean OS for patients with low risk, intermediate low risk, intermediate high risk and high risk was 10.46 +/- 1.02, 6.46 +/- 1.79, 4.50 +/- 1.20 and 1.15 +/- 0.46 years, respectively. Univariate analysis (log-rank test) for prognostic factors also revealed elevated LDH, B-symptoms and extranodal involvement as significant factors for OS. The presence of bulky disease (>7.5 cm), advanced stage III/IV and bone marrow involvement did not influence OS. In conclusion, it is evident that histological subtype and IPI-score have a strong prognostic impact on OS in pts with T-cell NHL. Thus, the distribution of risk factors in patients with T-cell NHL may be more important for OS than T-cell histology per se.
机译:T细胞NHL占所有恶性淋巴瘤的10-15%,因此很难进行系统的前瞻性临床试验。因此,近年来T细胞表型的预后意义一直是一个有争议的问题。回顾性分析1992年至1997年在单一机构中收集的681例NHL患者,确定了66例T细胞NHL患者。根据REAL分类,组织学如下:28例外周T细胞淋巴瘤(PTCL),19例大细胞间变性淋巴瘤(LCAL),12例前体淋巴母细胞淋巴瘤(Lb)和7例AILD。含多药蒽环类的方案在91%的病例中用作初始治疗。在过去的6年中,T细胞NHL占我们机构所有NHL患者的9.8%。一线治疗期间总体缓解率为76%,进展性疾病为21%,死亡3%。平均总生存(OS)为8.22 +/- 0.94年。四个不同的组织学亚组之间的OS有显着差异(对数秩P = 0.0288)。 LCAL:平均OS 11.05 +/- 1.55年(95%CI 8.00-14.09);磅:平均OS 7.09 +/- 1.40年(95%CI 4.33-9.84); PTCL:平均6.62 +/- 1.17年(95%CI 4.33-8.90); AILD:1.54 +/- 0.44年(95%CI 0.67-2.40)。对于根据国际预后指数(IPI)评分进行分类的患者,OS亦存在显着差异(对数等级P = 0.002)。低危,中低危,中高危和高危患者的平均OS分别为10.46 +/- 1.02、6.46 +/- 1.79、4.50 +/- 1.20和1.15 +/- 0.46年。对预后因素的单因素分析(对数秩检验)还显示LDH升高,B症状和结外受累是OS的重要因素。体积大的疾病(> 7.5 cm),III / IV期晚期和骨髓受累并不影响OS。总之,很明显,组织学亚型和IPI评分对T细胞NHL患者的OS有很强的预后影响。因此,对于OS,危险因素在T细胞NHL患者中的分布可能比T细胞组织学本身更重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号